All clinical and/or microbiological failures must be presented separately according to the infecting bacterium, MIC
and site of infection.
In vitro data must be presented as MICs, not simply as `susceptible' or `resistant', for individual bacterial species relevant
to the anticipated use of the drug.Quality control data must be
generated and recorded for all clinical isolate susceptibility
determinations.